**Core tip:** Small-cell lung cancer (SCLC) is a special type of lung cancer that belongs to highly aggressive neuroendocrine tumors. Classical radiotherapy and chemotherapy have a plateauing effect. Immunotherapy is becoming an important treatment strategy for SCLC. In this article, we review the recent advances in immunotherapy for SCLC.

INTRODUCTION
============

Small-cell lung cancer (SCLC) accounts for 13%-15% of all lung cancers. In the past two decades, little progress has been made in the treatment of SCLC, and radiotherapy and chemotherapy remain the mainstay of treatment. However, disease relapse or drug resistance can occur in almost all patients, and currently available options are limited. Most SCLC cases are still incurable\[[@B1]\]. Although many studies have explored gene mutations in SCLC, molecularly targeted therapies for SCLC gene abnormalities are still under investigation. Small-molecule antiangiogenic drugs (*e.g*., anlotinib) have made some progress in treating SCLC but with limited efficacy. Immunotherapy with checkpoint inhibitors for SCLC has lagged behind that for non-small cell lung cancer. Nevertheless, the role of immunotherapy in SCLC has been increasingly recognized.

In this review, we summarize the current status of nonspecific immunotherapy, vaccines, and immune checkpoint inhibitors (ICIs) in the treatment of SCLC.

NONSPECIFIC IMMUNOTHRAPY
========================

Interferons
-----------

Interferons (IFNs) are a group of proteins and glycoproteins produced by cells in response to viral stimuli. They have a wide range of regulatory effects on normal cells, tumor cells, and host immune defense cells by inhibiting cell growth and changing the structure, surface antigen expression, and differentiation/function of cells\[[@B2]\]. Early clinical studies have shown that IFN-α monotherapy may halt the growth of lung cancer\[[@B3]\]. In a multicenter randomized Phase III study on chemotherapy plus IFN-α treatment for SCLC, 209 patients were randomly divided into three groups: Group A was treated with chemotherapy alone (intravenous injection of cisplatin 70 mg/m^2^ on day 1 and intravenous injection of etoposide 100 mg/m^2^ on days 1, 2 and 3, every 28 d); Group B received chemotherapy + natural IFN-α (3 MU, three times/wk, intramuscularly); and Group C received chemotherapy + recombinant IFNα-2a (3 MU, three times/wk, intramuscularly). The results of the study showed that survival did not significantly differ among these three groups\[[@B4]\]. It is still unclear which combinations between IFN-α and other treatments can achieve better outcomes.

Interleukin-2
-------------

Interleukin-2 (IL-2) is a cytokine that can bind to specific receptors that are constitutively expressed on T cells and natural killer cells and mediate their immunostimulating effects\[[@B5]\]. Some studies have shown that the level of IL-2 secretion in SCLC patients at diagnosis may be related to prognosis\[[@B6],[@B7]\]. A clinical study showed that exogenous IL-2 may be effective in SCLC patients\[[@B8]\]. Meazza et al\[[@B9]\] found that *IL-2* gene transfection in IL-2R-negative SCLC cell lines might activate nonspecific effector cells and thus eliminate tumorigenicity in nude mice, and IL-2-transfected cells produce a local bystander effect on the growth of wild-type tumor cells\[[@B9]\]. However, another study found that the expression of Fas-ligand (CD95L) is upregulated in a variety of epithelial tumors including SCLC. As a result, cytotoxic T cells do not enter the tumor microenvironment and thus do not exert their effects\[[@B10]\]. To date, the role of IL-2 in the treatment of SCLC has not been fully recognized.

VACCINES
========

The p53 tumor suppressor gene plays a pivotal role in controlling cell growth and differentiation. More than 90% of SCLC patients have *p53* gene mutations and p53 protein overexpression\[[@B11]\], which are mainly due to a single site mutation or abnormal degradation of wild-type (wt) p53. In a Phase I/II clinical trial, INGN-225 was generated in SCLC patients after infection with wt-*p53*-containing adenovirus constructs, and the result confirmed the safety of INGN-225. Furthermore, more than 40% of patients showed an immune response. It was also found that the response rate was higher in patients who had just completed chemotherapy\[[@B12]\]. A similar conclusion was reached in a clinical trial that used the combination of p53 cancer vaccine with chemotherapy in 29 patients with extensive-stage (ES)-SCLC\[[@B13]\]. Since the role of the p53 vaccine for SCLC is still under investigation in clinical trials, more high-level evidence is still needed. A Phase II study on personalized peptide vaccination (PPV) in 46 patients with advanced SCLC revealed immune enhancement without severe adverse events and overall survival (OS) benefits after PPV, suggesting that the combination of PPV with chemotherapy may be a promising strategy for treating SCLC\[[@B13]\]. Phase III randomized controlled clinical trials are needed.

iCIs
====

Immune microenvironment of SCLC
-------------------------------

Most SCLC cases are associated with smoking. Quitting smoking and low tar inhalation can lower the incidence of SCLC\[[@B14]\]; in contrast, long-term exposure to carcinogens in tobacco smoke may increase the tumor mutation burden (TMB)\[[@B15]\]. In addition, tobacco exposure causes high-frequency inactive mutations of *TP53* and *RB1*, and their deletion can lead to high instability of the genome\[[@B16]\]. Studies have confirmed that, compared with other lung cancers, SCLC is associated with higher expression of DNA damage response (DDR) pathway mediators\[[@B17]-[@B19]\]. These genes are associated with high TMB in SCLC patients, which sheds new light on the research and development of DDR pathway-targeted drugs and on immunosuppression through a cascade of interactions. There are still negative immune factors in the microenvironment. For example, tumor-infiltrating lymphocytes (TILs) in SCLC are significantly correlated with the low expression of major histocompatibility complex class I (MHC-I) molecules and antigen presentation of cytotoxic T lymphocytes. Studies have shown absent or reduced MHC-I antigen expression and low TIL levels in SCLC patients; additionally, most lymphocytes are distributed at the edge rather than center of the tumor. Thus, low MHC-I antigen expression leads to reduced T-cell recruitment, resulting in decreased TIL infiltration inside the tumor, which is a negative predictive factor for outcome to immunotherapy. The proportions of CD3^+^ and CD8^+^ infiltrating lymphocytes are markedly decreased in the tumor microenvironment of SCLC. During biopsies performed before and after treatment, immunophenotype characterization has shown that 64% were immune-excluded phenotype, 21% were inflamed, and 14% were immune desert\[[@B20]\].

Cytotoxic T lymphocyte-associated antigen 4 inhibitors
------------------------------------------------------

Cytotoxic T lymphocyte-associated (CTLA) antigen is present in regulatory T cells and its expression is dependent on forkhead box P3. Mice with regulatory T cells that lack CTLA-4 protein expression were recently shown to develop lethal autoimmunity, revealing that regulatory T cell expression of CTLA-4 is necessary for immune suppression and prevention of *in vivo* autoimmunity\[[@B21]\].

CTLA-4 is a member of the CD28-B7 superfamily; it can be expressed on activated T cells and plays a role in downregulating T-cell activity. It is a key negative regulator in the early stage of T-cell activation\[[@B22],[@B23]\]. CTLA-4 inhibitors block CTLA-4-driven inhibitory signaling pathways and prevent the interactions of this receptor with its ligands CD80 and CD86 on antigen-presenting cells, leading to activation and proliferation of tumor-specific T cells and restriction of immune escape\[[@B24]\]. In a Phase II trial that compared ipilimumab plus paclitaxel with carboplatin and paclitaxel monotherapy in patients with ES-SCLC, programmed death ligand (PD-L) 1 expression level was not stratified. Immune-related response criteria were used to assess the treatment response. Ipilimumab plus chemotherapy improved the immune-related progression-free survival (PFS)\[[@B25]\] compared with chemotherapy alone. However, in a randomized Phase III trial (CA184-156) that compared the efficacy of ipilimumab plus etoposide and platinum *vs* etoposide and platinum in treating ES-SCLC, the median OS was 11.0 mo (95% confidence interval \[CI\]: 10.45--11.33) in patients treated with ipilimumab plus chemotherapy and 10.9 mo (95%CI: 10.02--11.50) in the chemotherapy plus placebo group, showing no significant improvement (hazard ratio \[HR\]: 0.94; 95%CI: 0.81--1.09; *P* = 0.3775). Ipilimumab combined with standard chemotherapy does not improve OS and PFS of patients with ES-SCLC. The possible explanation may be that ipilimumab combined with standard chemotherapy does not activate T cells in the tumor microenvironment, and peripheral T-cell activation alone may not be effective in eliciting a sufficiently potent antitumor response in SCLC. Chemotherapy may also limit the proliferation and activation of T cells\[[@B26]\].

PD-1 inhibitors
---------------

PD-1 is a receptor on T cells. It can counter T-cell proliferation under the action of either one of its ligands, PD-L1 or PD-L2, enabling tumor cells to escape immune eradication and achieve proliferation and metastasis\[[@B27]\]. PD-1 inhibitors block the binding of PD-L1 and PD-L2 to the PD-1 receptor of T cells, thereby activating T cells to recognize and kill tumor cells and eventually achieve an antitumor immune response\[[@B28]\].

Nivolumab
---------

In a nonrandomized Phase I/II multicenter, open-label trial (CheckMate 032), ES-SCLC patients who had previously received second-line or higher chemotherapy were treated with the PD-1 inhibitor nivolumab in different ways or in combination with ipilimumab. A total of 216 patients were divided into four groups: Nivolumab 3 mg/kg (*n* = 98); ipilimumab 1 mg/kg + nivolumab 1 mg/kg (*n* = 3); ipilimumab 3 mg/kg + nivolumab 1 mg/kg (*n* = 61); ipilimumab 1 mg/kg + nivolumab 3 mg/kg (*n* = 54). After four cycles of treatment, maintenance treatment with nivolumab 3 mg/kg was applied. Objective response rate (ORR) was the primary endpoint, which was 4% (10/98 patients), 33% (1/3), 23% (14/61), and 19% (10/54) in these four groups, respectively\[[@B29]\]. Notably, in the pooled cohort, the ORR was 22.3% in patients with high TMB (248 mutations) and only 4.8% in patients with low TMB (\< 143 mutations)\[[@B30]\]. No correlation was found between PD-L1 expression and treatment response. Based on data from the Phase I/II CheckMate-032 basket trial, nivolumab was granted accelerated approval by the United States Food and Drug Administration as third-line and later-line treatment for SCLC. Another Phase III CheckMate 451 study (NCT02538666) analyzed the efficacy of nivolumab monotherapy (240 mg), nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg), and placebo in maintenance therapy\[[@B30]\]. The study did not reach its primary endpoint (comparison of OS between the combination and placebo groups). OS in these two groups was 9.2 and 9.6 mo, respectively (HR: 0.92, 95%CI: 0.75--1.12; *P* = 0.37), and the 1-year OS rate was 41% and 40%, respectively\[[@B31]\]. Another large-scale Phase III trial (CheckMate 331; NCT02481830) enrolled 569 patients and explored the efficacy of nivolumab monotherapy *versus* chemotherapy as second-line treatment for ES-SCLC. Platinum-sensitive relapse was noted in 56% of these patients, but OS showed no significant difference between these two groups (7.5 mo *vs* 8.4 mo, HR: 0.86, 95%CI: 0.72-1.04; *P* = 0.11)\[[@B32]\].

Pembrolizumab
-------------

The KEYNOTE-158 study (NCT02628067) was a Phase II trial involving 11 solid tumors and included 107 treated ES-SCLC patients. The primary endpoint ORR was 18.7%, and the median PFS and OS were 2 and 9.1 mo, respectively\[[@B33]\]. Similarly, the KEYNOTE-028 study analyzed the effectiveness and safety of pembrolizumab in patients with previously treated SCLC; however, in this study, PD-L1 expression level ≥ 1% was used as a screening condition, and the therapeutic dose was increased to 10 mg/kg every 2 wk. The ORR and OS were 33.3% and 9.7 mo, respectively\[[@B33],[@B34]\]. The study was limited by its Phase I design and small sample size.

PD-L1
-----

PD-L1 is a fully human anti-PD-L1 monoclonal antibody that competes with B7-1 and PD-1 on T cells to activate T cells, overcome tumor cell escape, and restore tumor-specific T-cell immunity\[[@B35]\]. A multination, randomized, double-blind, placebo-controlled Phase III trial IMpower-133 (NCT02763579) was performed to evaluate the therapeutic effect of atezolizumab plus carboplatin and etoposide in treatment-naïve patients with ES-SCLC. A total of 403 treatment-naïve ES-SCLC patients were included and randomized into two groups in a 1:1 ratio: Chemotherapy + placebo and chemotherapy + atezolizumab (1200 mg every 3 wk)\[[@B36]\]. The two primary endpoints were PFS and OS. PFS was 5.2 mo in the atezolizumab group and 4.3 mo in the placebo group (HR: 0.77; 95%CI: 0.62-0.96; *P* = 0.02); OS was 12.3 mo in the atezolizumab group and 10.3 mo in the placebo group (HR: 0.7, 95%CI: 0.54-0.91; *P* = 0.007); and 1-year survival rate was 51.7% and 38.2%, respectively\[[@B37]\]. Notably, the OS curves began to separate after about 7 mo, which indicated the superiority of the atezolizumab group. Such separation continued after a median follow-up of 13.9 mo. The ORR between these two groups was 60.2% and 64.4%, respectively, suggesting that some patients may achieve longer benefits. However, chemotherapy + atezolizumab also resulted in more adverse reactions, and the rate of drug discontinuation due to adverse reactions was 11.1% and 3.1%, respectively, in these two groups\[[@B37]\]. IMpower133 is the first Phase III study with an immunotherapy-based combination to show improvement in PFS and OS in the initial treatment of ES-SCLC. Accordingly, the National Comprehensive Cancer Network guidelines list EC combined with atezolizumab as a Level I recommendation\[[@B38]\]. Another Phase II trial (IFCT-1603; NCT03059667) compared the effectiveness and safety of atezolizumab (1200 mg every 3 wk) with those of chemotherapy (topotecan or the original treatment regimen). Among the 73 patients enrolled, 64.4% had platinum-sensitive recurrence. The primary endpoint was ORR at 6 wk, which was 2.3% and 10% in the atezolizumab and chemotherapy groups; and PFS was 4.3 and 1.4 mo, respectively (HR: 2.26; 95%CI: 1.3-3.93; *P* = 0.004). However, the OS showed no significant difference between these two groups (9.5 mo *vs* 8.7 mo, HR: 0.84, 95%CI: 0.45-1.58; *P* = 0.6)\[[@B39]\].

Durvalumab
----------

CASPIAN is the second study that proved the effectiveness of PD-L1 monoclonal antibody as the first-line treatment for ES-SCLC. A total of 805 patients were randomly assigned to durvalumab + platinum-etoposide (*n* = 268), durvalumab + tremelimumab + platinum--etoposide *(n* = 268), and platinum-etoposide alone (*n* = 269). According to the preliminary data, the PFS of the durvalumab combination group was 5.1 mo (95%CI: 4.7-6.2 mo), PFS of the chemotherapy-only group was 5.4 mo (95%CI: 4.8-6.2 mo), the 6-mo PFS rate was 45% (95%CI: 39.3%-51.3%) and 46% (95%CI: 39.3%-51.7%), the 12-mo PFS rate was 18% (95%CI: 13.1%-22.5%) and 5% (95%CI: 2.4%-8.0%), and the OS was 13.0 mo with durvalumab plus platinum + etoposide and 10.3 mo with platinum + etoposide\[[@B40]\].

ICIs combined with poly (ADP ribose) polymerase inhibitors
----------------------------------------------------------

Sen et al\[[@B41]\] characterized the increased expression of DDR protein in SCLC by using reverse phase protein array, a functional proteomics technique\[[@B41]\]. They found strong synergy between immune-checkpoint blockade and DDR inhibitors; these agents increased the levels of TILs through innate immune responses and showed synergistic effects with anti-PD-L1 therapy in multiple SCLC models. Further studies showed that the antitumor immune response targeting poly (ADP ribose) polymerase (PARP) developed through the STING-TBK1-IRF3 pathway in SCLC, which offers theoretical support for the combination of PARP inhibitors with anti-PD-L1 antibodies\[[@B42]\]. A Phase II clinical trial (Registration No: NCT02484404) explored the combination of a PARP inhibitor with anti-PD-L1 monoclonal antibody for SCLC. A total of 20 patients with recurrent SCLC were included. The median age was 64 years, and the diseases were platinum refractory or resistant in 60% of the patients. After enrollment, they were treated with durvalumab (anti-PD-L1 monoclonal antibody) + olaparib (a PARP inhibitor). Of 19 evaluable patients, the ORR was 10.5% (*n* = 2). Clinical benefit was observed in four patients (21.1%, 95%CI, 6.1%-45.6%) with confirmed responses or prolonged stable disease (≥ 8 mo)\[[@B43]\]. Notably, biopsy specimens during their study suggested that tumor immune phenotypes might be relevant for SCLC responses to immune checkpoint blockade combinations. The most common treatment-related adverse events were anemia (80%), lymphopenia (60%), and leukopenia (50%)\[[@B43]\].

ICIs combined with radiotherapy
-------------------------------

Radiotherapy can influence the immune system and its interactions with cancer cells and tumors, producing cytokines that recruit anti-tumor immune cells, increasing the exposure of tumor antigens\[[@B44]\]. The use of radiotherapy may enhance efficacy of inmunotherapy.

Hendriks et al\[[@B44]\] evaluated in a Phase I 3 plus 3 design increasing doses of pembrolizumab (maximum 200 mg) every 3 wk combined with thoracic radiotherapy (45 Gy per 15 daily fractions) administered sequentially after induction of platinum-etoposide chemotherapy in extensive-stage SCLC. The results showed that the patients were generally well tolerated, with median PFS (6.1 mo) and median OS (8.4 mo). The combination treatment did not appear to improve survival\[. Therefore, there is still a need for more exploration and research on the combined treatment model.

CONCLUSION
==========

Immunotherapy for SCLC has included IFN, IL, immune adjuvants, and vaccines in recent decades (several important studies are summarized in Table [1](#T1){ref-type="table"}). However, their applications lack support from high-level evidence, and most of these therapies are still under investigation in clinical trials. SCLC is typically featured by high TMB, unstable *TP53* and *RB1* genes, and high mutation rate of DDR pathway. It has a lower expression level of PD-LI than other lung cancers. Certain advances have been made in the use of ICIs. Combination of first-line ICIs with chemotherapy for ES-SCLC has been confirmed by two large prospective studies, and is recommended by the National Comprehensive Cancer Network guidelines. However, the role of ICIs when used as later-line drugs warrants further study. Although both PD-L1 and TMB are still not useful biomarkers, further investigations on the immune microenvironment may be helpful in estimating the prognosis of immunotherapy. As we are in an era of Immune 2.0, there are theoretical bases for combination of immunotherapy and radiotherapy and for combinations of antiangiogenic drugs targeting the DDR pathway, although more clinical research is needed. In general, advances in immunotherapy and combinations of different treatment strategies have shed new light on the treatment of ES-SCLC.

###### 

Immune checkpoint inhibitors and relevant clinical studies

                                  **Ref**.     **Method**                                                                                                                                                        **PFS**              **OS**                            **ORR (%)**
  --------------- --------------- ------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- --------------------------------- --------------------------------------
  Ipilimumab      CA184-156       \[[@B26]\]   Ipilimumab plus Etoposide and Platinum *vs* Placebo plus Etoposide and Platinum                                                                                   4.6 mo *vs* 4.4 mo   11.0 mo *vs* 10.9 mo              \-
  Nivolumab       CheckMate 032   \[[@B29]\]   \(1\) Nivolumab 3 mg/kg; (2) Ipilimumab 1 mg/kg + Nivolumab 1 mg/kg; (3) Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg; and (4) Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg   1.4 mo               5.6 mo                            \(1\) 10; (2) 33; (3) 23; and (4) 19
                  CheckMate 451   \[[@B31]\]   Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg q3w *vs* Nivolumab 240 mg q2w *vs* Placebo                                                                                 \-                   9.2 mo *vs* 10.4 mo *vs* 9.6 mo   \-
                  CheckMate 331   \[[@B32]\]   Nivolumab 240 mg q2w *vs* Topotecan                                                                                                                               \-                   7.5 mo *vs* 8.4 mo                13.7 *vs* 16.5
  Pembrolizumab   KEYNOTE-158     \[[@B33]\]   Pembrolizumab 200 mg q3w                                                                                                                                          2 mo                 9.1 mo                            18.7
  Atezolizumab    IMpower-133     \[[@B37]\]   Atezolizumab + Etoposide and Carboplatin *vs* Placebo + Etoposide and Carboplatin                                                                                 5.2 mo *vs* 4.3 mo   12.3 mo *vs* 10.3 mo              \-
  Durvalumab      CASPIAN         \[[@B40]\]   Durvalumab plus Etoposide and Platinum *vs* Etoposide and Platinum                                                                                                5.1 mo *vs* 5.4 mo   13.0 mo *vs* 10.3 mo              \-

PFS: Progression-free survival; OS: Overall survival; ORR: Objective response rate.
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